For combined immunotherapy, a preclinical study on the Lewis lung carcinoma tumor model showed that combination therapy of IDO inhibitor with radiotherapy can reduce the expression of PD-L1 and Treg and promote the maturation of dendritic cells in the TME. Here, IDO1 is linked to neoplasm.